Women who underwent CAR T-cell therapy later carried pregnancies to term without health problems, according to a report from Technology Networks published on 23 September 2026.
The outlet reported the outcome as a notable finding, given that CAR T-cell therapy is an intensive treatment typically used in serious illness. The report did not specify how many women were involved, which conditions they were treated for, or where the research was carried out.
CAR T-cell therapy works by modifying a patient's own immune cells so they can target diseased cells. Because the treatment involves altering cells and is often paired with other aggressive therapies, questions have lingered about its possible effects on fertility and on pregnancy later in life. The Technology Networks report speaks to that question, indicating that healthy pregnancies followed treatment in the cases described.
The report offers no detail on the timing between therapy and conception, the ages of the women, or whether any complications occurred during pregnancy or delivery. It also does not say whether the pregnancies were tracked as part of a formal study or recorded through follow-up care.
The finding matters for patients of childbearing age who are weighing treatment options and for clinicians who counsel them. Fertility preservation is often discussed before cancer treatment begins, and evidence that pregnancy remains possible after CAR T-cell therapy could shape those conversations.
What to watch next: fuller data on the number of women, their diagnoses, and long-term outcomes for both mothers and children, which the current report does not provide.
